Cargando…
Evaluation of the Optimal Manufacturing Protocols and Therapeutic Properties of Mesenchymal Stem/Stromal Cells Derived from Wharton’s Jelly
Wharton’s jelly (WJ) from the umbilical cord (UC) is a good source of mesenchymal stem/stromal cells (MSCs), which can be isolated and used in therapy. Current knowledge shows that even small changes in the cell environment may result in obtaining a subpopulation of cells with different therapeutic...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820979/ https://www.ncbi.nlm.nih.gov/pubmed/36614096 http://dx.doi.org/10.3390/ijms24010652 |
_version_ | 1784865588848361472 |
---|---|
author | Sypecka, Monika Bzinkowska, Aleksandra Sulejczak, Dorota Dabrowski, Filip Sarnowska, Anna |
author_facet | Sypecka, Monika Bzinkowska, Aleksandra Sulejczak, Dorota Dabrowski, Filip Sarnowska, Anna |
author_sort | Sypecka, Monika |
collection | PubMed |
description | Wharton’s jelly (WJ) from the umbilical cord (UC) is a good source of mesenchymal stem/stromal cells (MSCs), which can be isolated and used in therapy. Current knowledge shows that even small changes in the cell environment may result in obtaining a subpopulation of cells with different therapeutic properties. For this reason, the conditions of UC transportation, cell isolation, and cultivation and the banking of cells destined for clinical use should be unified and optimized. In this project, we tried various protocols for cell vs. bioptat isolation, banking, and transport in order to determine the most optimal. The most efficient isolation method of WJ-MSCs was chopping the whole umbilical matrix with a scalpel after vessel and lining membrane removal. The optimal solution for short term cell transportation was a multi-electrolyte fluid without glucose. Considering the use of WJ-MSCs in cell therapies, it was important to investigate the soluble secretome of both WJ bioptats and WJ-MSCs. WJ-MSCs secreted higher levels of cytokines and chemokines than WJ bioptats. WJ-MSCs secreted HGF, CCL2, ICAM-1, BDNF, and VEGF. Since these cells might be used in treating neurodegenerative disorders, we investigated the impact of cerebrospinal fluid (CSF) on WJ-MSCs’ features. In the presence of CSF, the cells expressed consecutive neural markers both at the protein and gene level: nestin, β-III-tubulin, S-100-β, GFAP, and doublecortin. Based on the obtained results, a protocol for manufacturing an advanced-therapy medicinal product was composed. |
format | Online Article Text |
id | pubmed-9820979 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98209792023-01-07 Evaluation of the Optimal Manufacturing Protocols and Therapeutic Properties of Mesenchymal Stem/Stromal Cells Derived from Wharton’s Jelly Sypecka, Monika Bzinkowska, Aleksandra Sulejczak, Dorota Dabrowski, Filip Sarnowska, Anna Int J Mol Sci Article Wharton’s jelly (WJ) from the umbilical cord (UC) is a good source of mesenchymal stem/stromal cells (MSCs), which can be isolated and used in therapy. Current knowledge shows that even small changes in the cell environment may result in obtaining a subpopulation of cells with different therapeutic properties. For this reason, the conditions of UC transportation, cell isolation, and cultivation and the banking of cells destined for clinical use should be unified and optimized. In this project, we tried various protocols for cell vs. bioptat isolation, banking, and transport in order to determine the most optimal. The most efficient isolation method of WJ-MSCs was chopping the whole umbilical matrix with a scalpel after vessel and lining membrane removal. The optimal solution for short term cell transportation was a multi-electrolyte fluid without glucose. Considering the use of WJ-MSCs in cell therapies, it was important to investigate the soluble secretome of both WJ bioptats and WJ-MSCs. WJ-MSCs secreted higher levels of cytokines and chemokines than WJ bioptats. WJ-MSCs secreted HGF, CCL2, ICAM-1, BDNF, and VEGF. Since these cells might be used in treating neurodegenerative disorders, we investigated the impact of cerebrospinal fluid (CSF) on WJ-MSCs’ features. In the presence of CSF, the cells expressed consecutive neural markers both at the protein and gene level: nestin, β-III-tubulin, S-100-β, GFAP, and doublecortin. Based on the obtained results, a protocol for manufacturing an advanced-therapy medicinal product was composed. MDPI 2022-12-30 /pmc/articles/PMC9820979/ /pubmed/36614096 http://dx.doi.org/10.3390/ijms24010652 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sypecka, Monika Bzinkowska, Aleksandra Sulejczak, Dorota Dabrowski, Filip Sarnowska, Anna Evaluation of the Optimal Manufacturing Protocols and Therapeutic Properties of Mesenchymal Stem/Stromal Cells Derived from Wharton’s Jelly |
title | Evaluation of the Optimal Manufacturing Protocols and Therapeutic Properties of Mesenchymal Stem/Stromal Cells Derived from Wharton’s Jelly |
title_full | Evaluation of the Optimal Manufacturing Protocols and Therapeutic Properties of Mesenchymal Stem/Stromal Cells Derived from Wharton’s Jelly |
title_fullStr | Evaluation of the Optimal Manufacturing Protocols and Therapeutic Properties of Mesenchymal Stem/Stromal Cells Derived from Wharton’s Jelly |
title_full_unstemmed | Evaluation of the Optimal Manufacturing Protocols and Therapeutic Properties of Mesenchymal Stem/Stromal Cells Derived from Wharton’s Jelly |
title_short | Evaluation of the Optimal Manufacturing Protocols and Therapeutic Properties of Mesenchymal Stem/Stromal Cells Derived from Wharton’s Jelly |
title_sort | evaluation of the optimal manufacturing protocols and therapeutic properties of mesenchymal stem/stromal cells derived from wharton’s jelly |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820979/ https://www.ncbi.nlm.nih.gov/pubmed/36614096 http://dx.doi.org/10.3390/ijms24010652 |
work_keys_str_mv | AT sypeckamonika evaluationoftheoptimalmanufacturingprotocolsandtherapeuticpropertiesofmesenchymalstemstromalcellsderivedfromwhartonsjelly AT bzinkowskaaleksandra evaluationoftheoptimalmanufacturingprotocolsandtherapeuticpropertiesofmesenchymalstemstromalcellsderivedfromwhartonsjelly AT sulejczakdorota evaluationoftheoptimalmanufacturingprotocolsandtherapeuticpropertiesofmesenchymalstemstromalcellsderivedfromwhartonsjelly AT dabrowskifilip evaluationoftheoptimalmanufacturingprotocolsandtherapeuticpropertiesofmesenchymalstemstromalcellsderivedfromwhartonsjelly AT sarnowskaanna evaluationoftheoptimalmanufacturingprotocolsandtherapeuticpropertiesofmesenchymalstemstromalcellsderivedfromwhartonsjelly |